Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01922089 · ClinicalTrials.gov registry record · Phase 2
Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 498
- Enrollment target
NCT01922089 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 498 participants.
The verdict
NCT01922089, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 498 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and tolerability of initiating LCZ696 in heart failure patients with reduced ejection fraction (HF-rEF) using conservative (reaching target dose over 6 weeks) and condensed (reaching target dose over 3 weeks) up-titration regimens.
Interventions
- DRUG LCZ696
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 498 participants |
| Start Date | 2013-11 |
| Est. Completion | 2014-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01922089
The ClinicalTrials.gov registry entry for NCT01922089 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 498 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LCZ696 is the first listed.
NCT01922089 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01922089 about?
NCT01922089 is a clinical study titled "Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients". The purpose of this study is to assess the safety and tolerability of initiating LCZ696 in heart failure patients with reduced ejection fraction (HF-rEF) using conservative (reaching target dose over 6 weeks) and condensed (reaching target dose over 3 weeks) up-titration regimens.
What is the current status of trial NCT01922089?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 498 participants. The study started on 2013-11. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01922089?
The interventions under investigation include: LCZ696 (DRUG).
Who is sponsoring clinical trial NCT01922089?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.